What do systematic reviews say?

Heparin vs low molecular weight heparin

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Heparin vs prostaglandin E1

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Heparin vs no treatment

It is very uncertain whether summary of findings: Heparin changes overall survival ( compared with no treatment (very low certainty).

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  HR 0.65
  1 study · 161 participants
  Very low

Glutamine vs placebo

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings 2: PLD alone vs other conventional chemotherapy

Summary of findings 2: PLD alone showed no clear difference in overall survival (OS) compared with other conventional chemotherapy (moderate certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.96 [0.77, 1.19]
  6 studies · 1995 participants
  Moderate

Summary of findings: Defibrotide vs no treatment

Summary of findings: Defibrotide showed no clear difference in overall survival ( compared with no treatment (low certainty).

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  HR 1.04 [0.54, 2.02]
  1 study · 356 participants
  Low

Summary of findings: Non‐intensive vs intensive follow‐up

Summary of findings: Non‐intensive showed no clear difference in overall survival compared with intensive follow‐up (high certainty).

• Follow‐up strategies for women treated for early breast cancer 2016 · Cochrane Headline outcomes only
  HR 0.98 [0.84, 1.15]
  2 studies · 2563 participants
  High

Summary of findings: Decentralised vs centralised follow‐up

Summary of findings: Decentralised showed no clear difference in overall survival compared with centralised follow‐up (moderate certainty).

• Follow‐up strategies for women treated for early breast cancer 2016 · Cochrane Headline outcomes only
  HR 1.07 [0.64, 1.78]
  1 study · 968 participants
  Moderate

Summary of Findings Table ‐ PBI?APBI vs WBRT

Summary of Findings Table ‐ PBI?APBI showed no clear difference in overall survival compared with WBRT (high certainty).

• Partial breast irradiation versus whole breast radiotherapy for early breast cancer 2021 · Cochrane Headline outcomes only
  HR 0.99 [0.88, 1.12]
  8 studies · 13175 participants
  High

Fresh frozen plasma vs no treatment

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Ursodeoxycholic acid vs placebo or no treatment

Summary of findings: Ursodeoxycholic acid showed no clear difference in overall survival ( compared with placebo or no treatment (low certainty).

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  HR 0.83 [0.59, 1.18]
  3 studies · 474 participants
  Low

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Summary of findings 1: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with alternative combination chemotherapy (moderate certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.93 [0.83, 1.04]
  5 studies · 2006 participants
  Moderate

Summary of findings 1: PLD with chemotherapy vs PLD alone

Summary of findings 3: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with PLD alone (moderate certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.92 [0.7, 1.21]
  1 study · 242 participants
  Moderate

Low molecular weight heparin vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Low molecular weight heparin vs prostaglandin E1

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Antithrombin III plus heparin vs heparin

The review found no eligible studies for this question.

• Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) vs no PMRT

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) probably leads to lower overall survival (OS) compared with no PMRT (moderate certainty).

• Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes 2023 · Cochrane Headline outcomes only
  HR 0.76 [0.6, 0.97]
  1 study · 552 participants
  Moderate

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Summary of findings: Molecular‐targeted therapy plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).

• Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
  HR 0.92 [0.8, 1.05]
  10 studies · 3843 participants
  Low

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy showed no clear difference in overall survival (OS) compared with placebo (maintenance therapy) (moderate certainty).

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  HR 0.81 [0.59, 1.13]
  2 studies · 1124 participants
  Moderate

Summary of findings table ‐ Calaspargase (11 doses, 2500 IU/m2, IV) vs PEG‐asparaginase (16 doses, 2500 IU/m2, IV)

• PEG‐asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 239 participants
  Moderate